Drospirenone/estetrol

Drug Profile

Drospirenone/estetrol

Alternative Names: E4/DRSP; Estelle; Estetrol/Drospirenone

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Estetra S.A.
  • Class Androstenes; Antiandrogens; Gonadal steroid hormones; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor beta modulators; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pregnancy

Most Recent Events

  • 04 May 2017 Estetra completes a phase I pharmacokinetics and safety trial in Pregnancy (Prevention) in Netherlands (PO) (NCT02874248)
  • 14 Dec 2016 Estetra initiates a phase II trial for Contraception in Netherlands (PO) (EudraCT2016-004267-40)
  • 01 Sep 2016 Phase-II clinical trials in Pregnancy (Prevention) in Netherlands (PO) (NCT02957630)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top